Early onset of selective serotonin reuptake inhibitor antidepressant action - Systematic review and meta-analysis

被引:282
作者
Taylor, Matthew J. [1 ]
Freemantle, Nick
Geddes, John R.
Bhagwagar, Zubin
机构
[1] Univ Oxford, Dept Psychiat, Warneford Hosp, Oxford OX3 7JX, England
[2] Yale Univ, Dept Psychiat, Sch Med, New Haven, CT USA
[3] Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham, W Midlands, England
基金
英国惠康基金;
关键词
D O I
10.1001/archpsyc.63.11.1217
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Context: Selective serotonin reuptake inhibitors (SSRIs) are often described as having a delayed onset of effect in the treatment of depression. However, some trials have reported clinical improvement as early as the first week of treatment. Objective: To test the alternative hypotheses of delayed vs early onset of antidepressant action with SSRIs in patients with unipolar depression. Data Sources: Trials identified by searching CENTRAL, The Cochrane Collaboration database of controlled trials (2005), and the reference lists of identified trials and other systematic reviews. Study Selection: Randomized controlled trials of SSRIs vs placebo for the treatment of unipolar depression in adults that reported outcomes for at least 2 time points in the first 4 weeks of treatment (50 trials from > 500 citations identified). Trials were excluded if limited to participants older than 65 years or specific comorbidities. Data Extraction: Data were extracted on trial design, participant characteristics, and outcomes by a single reviewer. Data Synthesis: Pooled estimates of treatment effect on depressive symptom rating scales were calculated for weeks 1 through 6 of treatment. In the primary analysis, the pattern of response seen was tested against alternative models of onset of response. The primary analysis incorporated data from 28 randomized controlled trials (n=5872). A model of early treatment response best fit the experimental data. Treatment with SSRIs rather than placebo was associated with clinical improvement by the end of the first week of use. A secondary analysis indicated an increased chance of achieving a 50% reduction in Hamilton Depression Rating Scale scores by 1 week (relative risk, 1.64; 95% confidence interval, 1.2-2.25) with SSRI treatment compared with placebo. Conclusions: Treatment with SSRIs is associated with symptomatic improvement in depression by the end of the first week of use, and the improvement continues at a decreasing rate for at least 6 weeks.
引用
收藏
页码:1217 / 1223
页数:7
相关论文
共 67 条
[1]  
ALDERSON P, 2004, COCHANE REV HDB
[2]   Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression [J].
Andreoli, V ;
Caillard, V ;
Deo, RS ;
Rybakowski, JK ;
Versiani, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (04) :393-399
[3]  
ANGST J, 1970, TOFRANIL, P36
[4]  
[Anonymous], 2004, DEPR MAN DEPR PRIM S
[5]  
[Anonymous], DEPRESSION, DOI DOI 10.1002/depr.3050030407
[6]   DEVELOPMENT OF BETA-ADRENERGIC-RECEPTOR SUBSENSITIVITY BY ANTIDEPRESSANTS [J].
BANERJEE, SP ;
KUNG, LS ;
RIGGI, SJ ;
CHANDA, SK .
NATURE, 1977, 268 (5619) :455-456
[7]   Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression [J].
Bech, P ;
Tanghoj, P ;
Cialdella, P ;
Andersen, HF ;
Pedersen, AG .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 (03) :283-290
[8]   Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor [J].
Bhagwagar, Z ;
Wylezinska, M ;
Taylor, M ;
Jezzard, P ;
Matthews, PM ;
Cowen, PJ .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (02) :368-370
[9]   Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression [J].
Bhagwagar, Z ;
Cowen, PJ ;
Goodwin, GM ;
Harmer, CJ .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (01) :166-168
[10]  
BLIER P, 1987, J CLIN PSYCHOPHARM, V7, pS24